When appropriate, we prescribe medications, including GLP-1s, to promote and maintain weight loss
Commercial / Employer Group & marketplace plans Coverage on BCBS commercial and employer plans is entirely affiliate-specific and employer-dependent
Moreover, palmatine was the most abundant alkaloid of FRP, which means we dont have to worry about palmatine being insufficient for widely used and in-depth development
With tirzepatide in EMBRAZE: 85% fat / 15% lean, vs 70/30 for tirz alone
Hypoglycaemia Risk When Combining These Medications Hypoglycaemia (blood glucose below 4.0 mmol/L) is the most important safety concern when taking glipizide and Rybelsus together
Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks
